Company news

Vertex Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

September 30, 2019

Vertex Reports Second-Quarter 2019 Financial Results

July 30, 2019

Vertex Appoints Charles Wagner as Chief Financial Officer

April 1, 2019

Investor Network: Vertex Pharmaceuticals Incorporated to Host Earnings Call

July 26, 2017

Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011

August 3, 2006

Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual Canaccord Adams Summer Seminar

August 2, 2006

Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results

July 26, 2006

Vertex Pharmaceuticals Announces the Date of its Second Quarter 2006 Financial Results Conference Call and Webcast

July 6, 2006

Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV

June 30, 2006

Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C

June 30, 2006

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

June 16, 2006

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences

June 9, 2006

Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients

May 23, 2006

Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients

May 22, 2006

Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis

May 17, 2006

GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV

May 16, 2006

Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting

May 11, 2006

Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients

April 29, 2006

New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950

April 26, 2006

Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results

April 25, 2006

Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)

April 5, 2006

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF

March 23, 2006

Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis

March 8, 2006

Vertex Pharmaceuticals Reports 2005 Financial Results

February 7, 2006

Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program

February 7, 2006

VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon

January 9, 2006

Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference

January 9, 2006

GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir

December 16, 2005

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

December 8, 2005

Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study

December 7, 2005

Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

December 5, 2005

Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $95.0 Million of its Convertible Senior Subordinated Notes Due 2011

November 28, 2005

AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor

November 11, 2005

Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting

November 9, 2005

Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations

October 31, 2005

Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results

October 26, 2005

Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis

October 4, 2005

New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track

October 3, 2005

Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock

September 9, 2005

Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results

July 27, 2005

← Newer news releases

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.